Efficacy
In the ITT population,
Optune Lua® with IOs or docetaxel provided a statistically significant 3.3-month improvement in overall survival1,2
13.2-month median OS with Optune Lua + IOs or docetaxel vs either alone (9.9 months)
Overall survival (primary endpoint met)
Statistically significant; HR 0.74 (95% CI 0.56–0.98); P=0.035
The ITT population received docetaxel or IOs (nivolumab, pembrolizumab or atezolizumab), as assigned by the physician, either together with Optune Lua or alone.2
In the Optune Lua + IO subpopulation,
Optune Lua with IO provided a statistically significant, 7.7-month improvement in overall survival1,2
Median OS nearly doubled with Optune Lua + IOs (18.5 months) vs IOs alone (10.8 months)
Overall survival (key secondary endpoint met)
Statistically significant HR 0.63 (95% CI 0.41–0.96); P=0.030
The ITT population received docetaxel or IO (nivolumab, pembrolizumab, or atezolizumab), as selected by the investigator, either together with Optune Lua or alone.
In the Optune Lua + docetaxel subpopulation,
Optune Lua with docetaxel provided a 2.4-month difference in overall survival, representing a positive trend1,2.
11.1-month median OS with Optune Lua + docetaxel vs docetaxel alone (8.7 months)
Overall survival (key secondary endpoint)
Not statistically significant; HR 0.81 (95% CI 0.55-1.19); P=0.28
See Optune Lua’s safety profile
CI, Confidence Interval; HR, Hazard Ratio; ICI, Immune Checkpoint Inhibitor; ITT, Intention-To-Treat; OS, Overall Survival
References: 1. Optune Lua. Instructions for Use for non small cell lung cancer. Novocure; 2023. 2. Leal T, Kotecha R, Ramlau R, et al. Tumor treating fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol. 2023;24(9):1002-1017. doi:10.1016/S1470-2045(23)00344-3